Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 4/20 | 0.34 |
| ▸ | NMT2 | O60551 | 2/20 | 0.34 |
| ▸ | NMT1 | P30419 | 2/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15745525 | 0.94 | APLNR (0.36) | APLNRNMT2NMT1CRHR1CRHR2 | |
| SCHEMBL15744687 | 0.94 | APLNR (0.40) | APLNRF2NMT2NMT1CRHR1 | |
| SCHEMBL2623712 | 0.83 | APLNR (0.40) | APLNRF2CRHR1CRHR2CAPN1 | |
| SCHEMBL26403878 | 0.82 | GRPR (0.43) | APLNRCAPN1 | |
| SCHEMBL26404291 | 0.80 | SLC18A2 (0.34) | APLNR | |
| SCHEMBL22387819 | 0.79 | CTSS (0.40) | CAPN1 | |
| SCHEMBL20648523 | 0.77 | APLNR (0.36) | APLNRGHSR | |
| SCHEMBL15745544 | 0.77 | CRHR1 (0.37) | APLNRF2CRHR1CRHR2GHSR | |
| SCHEMBL15745527 | 0.76 | APLNR (0.37) | APLNRCRHR1CRHR2GHSR | |
| SCHEMBL15744682 | 0.76 | MMP3 (0.40) | APLNRF2CRHR1CRHR2GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190700-A1 | Emetine Derivatives, Prodrugs Containing Same, And Methods Of Treating Conditions Using Same | BAKARE OLADAPO (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190700-A1 | Emetine Derivatives, Prodrugs Containing Same, And Methods Of Treating Conditions Using Same | EML4, MCL1, ERAP2 | APLNR 1503/4885F2 2994/4885NMT2 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.